Leyenda
: Ensayo clínico en reclutamiento
= 
; Ensayos clínico en curso
= 
-
- ALEMANIA
- Berlin
- NOT YET IDENTIFIED - DE
- In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX) (Phase IV) - DE - Terminated
- Not yet identified - DE
- Para más detalles
-
- ALEMANIA
- Berlin
- NOT YET IDENTIFIED - DE
- paradigm 2: A phase III multicentre, single-blind trial evaluating safety and efficacy, including pharmacokinetics, of NNC-0156-0000-0009 when used for treatment and prophylaxis of bleeding episodes in patients with Haemophilia B - DE
- Not yet identified - DE
- Para más detalles
-
- ALEMANIA
- Berlin
- NOT YET IDENTIFIED - DE
- A Phase II/III open-label, multicenter, safety and efficacy study of a recombinant coagulation Factor IX Albumin Fusion Protein (rIX-FP) in subjects with Hemophilia B - DE
- Not yet identified - DE
- Para más detalles
-
- BELGICA
- BRABANT WALLON
- LOUVAIN-LA-NEUVE
- Gait Evaluation in Haemophiliac Patients (observational).
- Pierre De Coubertin
- Institut d'Education Physique et Readaptation
- Para más detalles
-
- ESPAÑA
- Cataluña
- BARCELONA
- Recombinant Factor IX (BAX 326): Estudio en Fase 1/3, prospectivo, controlado, multicéntrico, evaluando la farmacocinética, eficacia, seguridad e inmunogenicidad en pacientes previamente tratados con hemofilia B severa o moderadamente severa (completado)
- Hospital Universitari General Vall d'Hebron
- Unidad de Hemofilia
- Para más detalles
-
- ESPAÑA
- Cataluña
- BARCELONA
- BAX 326 (Recombinant Factor IX): Evaluación de seguridad, inmunogenicidad, y eficacia hemostática en pacientes tratados previamente, con hemofilia B severa (nivel FIX < 1%) o moderadamente grave (nivel FIX <= 2%) - Continuación de un estudio
- Hospital Universitari General Vall d'Hebron
- Unidad de Hemofilia
- Para más detalles
-
- ESPAÑA
- Madrid
- NOT YET IDENTIFIED - ES
- Eficacia y seguridad de NNC 0078-0000-0007 en el tratamiento de episodios agudos de sangrado en pacientes con hemofilia congénita e inhibidores (Fase III) (completado)
- Not yet identified - ES
- Para más detalles
-
- ESPAÑA
- Madrid
- NOT YET IDENTIFIED - ES
- Estudio en fase II/III, abierto, multicéntrico, de seguridad y eficacia de la proteína recombinante de fusión que une el factor IX de coagulación con la albúmina (rIX-FP) en sujetos con hemofilia B
- Not yet identified - ES
- Para más detalles
-
- ESPAÑA
- Madrid
- NOT YET IDENTIFIED - ES
- Estudio de fase III, abierto y multicéntrico, de la farmacocinética, la seguridad y la eficacia de una proteína de fusión del factor IX recombinante de coagulación con la albúmina (rIX-FP) en niños con hemofilia B tratados previamente
- Not yet identified - ES
- Para más detalles
-
- ESPAÑA
- Madrid
- NOT YET IDENTIFIED - ES
- Ensayo abierto, multicentrico, sin control, para evaluar la eficacia y seguridad de NNC-0156-0000-0009 durante procedimientos quirúrgicos en pacientes con hemofilia B (Fase III)
- Not yet identified - ES
- Para más detalles
-
- ESPAÑA
- Madrid
- NOT YET IDENTIFIED - ES
- Seguridad y eficacia de NNC-0156-0000-0009 tras una exposición a largo plazo en pacientes con hemofilia B (Fase III)
- Not yet identified - ES
- Para más detalles
-
- FRANCIA
- ILE-DE-FRANCE
- PARIS
- An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of prophylactic administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients with Inhibitors (Phase II) - FR
- CHU Paris - Hôpital Necker - Enfants Malades
- Centre Régional de traitement de l'hémophilie François Josso
- Para más detalles
-
- FRANCIA
- NORD-PAS-DE-CALAIS
- LILLE
- FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor (Phase III) - FR
- CHRU de Lille - Centre de biologie pathologie génétique
- Service Hématologie-Transfusion
- Para más detalles
-
- B-LONG: An open-label multicenter study evaluating the safety, pharmacokinetics and efficacy of the Fc-recombinant, Long-acting Coagulation Factor IX (rFIXFc) fusion protein in the prevention and treatment of bleeding in previously treated patients with severe hemophilia B - FR
- CHRU Lyon - Hôpital Edouard Herriot
- Centre régional de traitement de l'hémophilie
- Para más detalles
-
- Phase I/II/III pharmacokinetic and outcome study of Inspiration's recombinant Factor IX product, IB1001, in subjects with hemophilia B - FR
- CHRU Lyon - Hôpital Edouard Herriot
- Centre régional de traitement de l'hémophilie
- Para más detalles
-
- FRANCIA
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX) (Phase IV) - FR
- Not yet identified - FR
- Para más detalles
-
- FRANCIA
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Paradigm 4: Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B - FR
- Not yet identified - FR
- Para más detalles
-
- FRANCIA
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Paradigm 3: An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B - FR
- Not yet identified - FR
- Para más detalles
-
- FRANCIA
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Paradigm 2: A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC-0156-0000-0009 when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Haemophilia B - FR
- Not yet identified - FR
- Para más detalles
-
- FRANCIA
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B - FR
- Not yet identified - FR
- Para más detalles
-
- FRANCIA
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- FEIBA NF: A prospective, open-label, randomized, parallel study to evaluate efficacy and safety of prophylactic versus on-demand treatment in subjects with hemophilia A or B and a high titer inhibitor - FR
- Not yet identified - FR
- Para más detalles
-
- FRANCIA
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Phase 1/2, Prospective, Dose-Escalation/Finding Study to Evaluate Pharmacokinetics and Immediate Tolerability of Recombinant Activated FVII (rFVIIa BI) in Patients with Hemophilia A or B and Inhibitors - FR
- Not yet identified - FR
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- FERRARA
- Gentamycin treatment of congenital coagulation factor VII or factor IX deficiency caused by nonsense mutations (phase II)
- Università degli Studi di Ferrara
- Laboratorio di Biologia Molecolare dell'Emostasi e Trombosi
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor (Phase III) - IT
- NOT YET IDENTIFIED - IT
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 2: A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC-0156-0000-0009 when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 3: An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 4: Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A Phase II/III open-label, multicenter, safety and efficacy study of a recombinant coagulation Factor IX Albumin Fusion Protein (rIX-FP) in subjects with Hemophilia B - IT
- NOT YET IDENTIFIED - IT
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 5: Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B
- NOT YET IDENTIFIED - IT
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A Phase II-III trial to evaluate the efficacy and safety of BAY86-6150
- NOT YET IDENTIFIED - IT
- Para más detalles
-
- ITALIA
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B
- NOT YET IDENTIFIED - IT
- Para más detalles
-
- REINO UNIDO (EL)
- Greater London
- LONDON
- An open label dose-escalation study of a self complementary adeno-associated viral vector (scAAV2/8-LP1-hFIXCO) for gene therapy of haemophilia B (Phase I/II)
- University College London
- Department of Haematology
- Para más detalles
